Landy 1999.

Methods	Single‐centre, double‐blind, randomised, parallel study: sertraline versus placebo No control for symptomatic/analgesic medications use
Participants	Country: USA N = 27 Sex: 2 M, 25 F Mean age: 36 (SD 8.6) Diagnosis: migraine with or without aura for 1 year or longer (according to International Headache Society Criteria, IHS 1988) Exclusion criteria: severe systemic illness, pregnancy, lactation, treated for a concomitant seizures or psychiatric disorder Recruitment: patients of the Wesley Headache Clinic
Interventions	N = 13 sertraline to a maximum of 100 mg/day N = 14 placebo Active treatment: 8 weeks
Outcomes	1. Headache Index = intensity ('1 = mild pain' to '3 = severe') x number of occurrences 2. Impairment Index = impairment ('1 = no impairment' to '3 = bed rest') * number of occurrences
Notes	11 drop‐outs (41%): Sertraline: 7 (6 did not complete the study, 1 for side effects: loss of appetite and insomnia) Placebo: 4 (2 did not return, 2 for side effects: anxiety, nausea, dizziness and sweating) Per protocol analysis No sample size calculation
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information
Allocation concealment (selection bias)	Unclear risk	No information
Blinding (performance bias and detection bias) All outcomes	Low risk	Patient, treating physician, and nurse were unaware of the group assignment
Incomplete outcome data (attrition bias) All outcomes	High risk	Substantial drop‐out rate, unbalanced, reasons not fully reported
Selective reporting (reporting bias)	Unclear risk	No information
Other bias	Unclear risk	Financial support not reported